Follow
IVAN MARQUEZ RODAS
IVAN MARQUEZ RODAS
Instituto de Investigación Sanitaria Gregorio Marañón
Verified email at salud.madrid.org
Title
Cited by
Cited by
Year
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
78132015
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
34922017
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England journal of medicine 381 (16), 1535-1546, 2019
29542019
Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma
J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ...
New England Journal of Medicine 377 (19), 1824-1835, 2017
21672017
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
FS Hodi, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CL Cowey, ...
The Lancet Oncology 19 (11), 1480-1492, 2018
13232018
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
MA Davies, P Saiag, C Robert, JJ Grob, KT Flaherty, A Arance, ...
The Lancet Oncology 18 (7), 863-873, 2017
6912017
Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 40 (2), 127, 2022
5642022
Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis
SP D’Angelo, J Larkin, JA Sosman, C Lebbé, B Brady, B Neyns, ...
Journal of Clinical Oncology 35 (2), 226, 2017
5382017
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled …
PA Ascierto, M Del Vecchio, M Mandalá, H Gogas, AM Arance, S Dalle, ...
The Lancet Oncology 21 (11), 1465-1477, 2020
4252020
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
E Perez-Ruiz, L Minute, I Otano, M Alvarez, MC Ochoa, V Belsue, ...
Nature 569 (7756), 428-432, 2019
3552019
Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb/IV CheckMate 511 trial
C Lebbé, N Meyer, L Mortier, I Marquez-Rodas, C Robert, P Rutkowski, ...
Journal of Clinical Oncology 37 (11), 867, 2019
3042019
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, ...
Therapeutic advances in medical oncology 10, 1758834017749748, 2018
2492018
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, PA Ascierto, R Dummer, C Robert, P Lorigan, A Van Akkooi, ...
Annals of oncology 31 (11), 1435-1448, 2020
1622020
Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats
J Blanco-Rivero, V Cachofeiro, V Lahera, R Aras-Lopez, ...
Hypertension 46 (1), 107-112, 2005
1602005
Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials
GV Long, JS Weber, J Larkin, V Atkinson, JJ Grob, D Schadendorf, ...
JAMA oncology 3 (11), 1511-1519, 2017
1582017
Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: combined analysis of two cohorts
P Sharma, S López-Tarruella, JA García-Saenz, C Ward, CS Connor, ...
Clinical cancer research 23 (3), 649-657, 2017
1392017
CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.
JD Wolchok, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, ...
Journal of Clinical Oncology 39 (15_suppl), 9506-9506, 2021
1182021
Deregulated miRNAs in Hereditary Breast Cancer Revealed a Role for miR-30c in Regulating KRAS Oncogene
M Tanic, K Yanowsky, C Rodriguez-Antona, R Andrés, I Márquez-Rodas, ...
PloS one 7 (6), e38847, 2012
1132012
Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel
P Sharma, S López-Tarruella, JA García-Saenz, QJ Khan, HL Gómez, ...
Clinical Cancer Research 24 (23), 5820-5829, 2018
1092018
Immunotherapeutic effects of intratumoral nanoplexed poly I: C
MA Aznar, L Planelles, M Perez-Olivares, C Molina, S Garasa, I Etxeberría, ...
Journal for immunotherapy of cancer 7, 1-16, 2019
1082019
The system can't perform the operation now. Try again later.
Articles 1–20